Some spin · most spun: Daily Mirror 32/100 See every outlet’s spin ↓Photo as used by Daily Mirror for “Grandad sues Ozempic maker Novo Nordisk claiming weight loss jab left him partially blind”How Daily Mirror framed it: The Daily Mirror's lead image shows a smiling older man in glasses and a blue shirt. Paired with the headline, the portrait gives the legal claim a personal, human-interest focus.
Jay Vandegriff says he developed vision loss after taking Ozempic for type 2 diabetes. His lawyer says he is seeking compensation from Novo Nordisk over an alleged failure to warn. The company disputes the personal injury claims, while regulators have issued warnings about a rare eye condition.
How the coverage differs
The Daily Mirror and Manchester Evening News both describe Jay's diabetes treatment, diagnosis and the FDA label warning; the WalesOnline material supplied contains only a headline and brief summary. Of the three supplied excerpts, only the Daily Mirror includes the MHRA's urgent advice for sudden or rapidly worsening sight loss, while only the Manchester Evening News includes Novo Nordisk's response. Neither full text mentions that diabetes itself raises NAION risk.
Jay Vandegriff, an Idaho resident, is suing Novo Nordisk over vision loss he alleges was caused by Ozempic, according to reports quoting him and his lawyer. He says he began treatment for type 2 diabetes in 2023. The company disputes the personal injury claims and says a causal relationship between semaglutide and the condition has not been established.S1S2
Vandegriff says he noticed a smudge in his left eye on Christmas Day 2024 and was subsequently diagnosed with non-arteritic anterior ischaemic optic neuropathy, or NAION. He describes continuing deterioration after stopping treatment and difficulty working and judging distances. These are his accounts of his symptoms and their effects.S1S2
His lawyer, Danielle Gold of Weitz & Luxenberg, says the firm has filed more than 100 cases, with another 100 to 150 pending in New Jersey Superior Court through other firms. She says Vandegriff seeks compensation for an alleged failure to warn. Those figures are the lawyer's account of the litigation.S1
Why it matters
On 9 November, the FDA required warnings about a potential increased risk of NAION across GLP-1 receptor agonist medicines. Its safety communication describes a rare condition that can cause permanent sight loss. The warning concerns a possible treatment risk; it does not decide what caused Vandegriff's individual injury or whether the manufacturer is liable.R1S1S2
Novo Nordisk told the Manchester Evening News that it considers the US personal injury lawsuits without merit and is defending them. It said it continues to assess clinical, epidemiological and post-marketing evidence. That is the company's position, alongside the plaintiffs' allegation that they were inadequately warned.S2
The background
The UK's MHRA issued semaglutide safety advice on 5 February 2026, describing the possible association with NAION as very rare. It explains that reduced blood flow to the optic nerve causes the condition and that type 2 diabetes itself increases the underlying risk. That background complicates attribution of an individual case.R2
New Jersey's Supreme Court designated the NAION claims as a separate multicounty litigation, assigning centralised management to Bergen County. A November 2025 court notice distinguishes these vision-loss cases from gastrointestinal-injury claims involving the same drug class. The document concerns case management, rather than findings on the merits of individual claims.R3
What happens next
The outcome of Vandegriff's claim remains unresolved in the material reviewed. For patients, the MHRA advises urgent attendance at eye casualty or A&E for sudden sight loss or rapidly worsening vision during semaglutide treatment. The FDA says patients who have experienced NAION should discuss continuing or stopping treatment with their clinician.S1S2R1R2
Fact check: every point labelled
What is confirmed, what is only reported, and what is claim or speculation. Every point links to its source.
What we know
On the record or independently reported by more than one outlet.
confirmedThe FDA required GLP-1 label warnings on 9 November 2026 about potential increased risk of rare NAION, which can cause permanent sight loss.R1
confirmedMHRA's 5 February 2026 advice describes a very rare possible semaglutide association; diabetes itself raises NAION risk, and the condition involves reduced optic-nerve blood supply.R2
confirmedThe New Jersey court notice assigns NAION cases to centralised Bergen County management separately from gastrointestinal cases, without deciding individual liability.R3
confirmedMHRA advises urgent eye casualty or A&E attendance for sudden sight loss or rapidly worsening vision; FDA advises discussion with a clinician about continued treatment after NAION.R1R2
Reported but not yet confirmed
Reported as fact, but from a single origin.
reportedDaily Mirror and Manchester Evening News: Vandegriff is an Idaho resident who was prescribed Ozempic for type 2 diabetes in 2023.S1S2
Claims and disputes
What people say. Not established fact.
claimedJay Vandegriff and Danielle Gold: Vandegriff is pursuing a claim alleging Ozempic caused vision loss and that warnings were inadequate.S1S2
claimedJay Vandegriff: He noticed left-eye symptoms on 25 December 2024, received a NAION diagnosis, and experienced further deterioration after stopping treatment, affecting work and distance judgement.S1S2
claimedDanielle Gold: Weitz & Luxenberg has filed more than 100 cases, with another 100 to 150 through other firms pending in New Jersey Superior Court.S1
disputedNovo Nordisk, disputed by Vandegriff and his lawyer: The personal injury claims lack merit and a causal relationship has not been established; plaintiffs allege medicine-related vision loss and inadequate warnings.S1S2
claimedNovo Nordisk: Novo Nordisk is defending the lawsuits and continues to assess clinical, epidemiological and post-marketing evidence.S2
Still unknown
The eventual court ruling on causation, warnings and liability in Vandegriff's case.
Key questions
Did Ozempic cause Vandegriff's vision loss?
That is his allegation. Novo Nordisk disputes the claim, and the material reviewed does not establish a court finding on causation.S1S2
What is NAION?
An optic-nerve condition associated with reduced blood supply that can cause sudden vision loss.R2
What changed in the US warning?
On 9 November the FDA required GLP-1 medicine labels to include information about a potential increased NAION risk.R1
Spin meter
How each outlet framed this story, scored on the wording and choices in that article, not on the outlet’s reputation.
Headlines compared: All three headlines foreground a grandfather's claim of partial blindness and his lawsuit. The Daily Mirror and Manchester Evening News call Ozempic a weight-loss jab, while WalesOnline describes it more generally as medication.
Daily MirrorFraming: Not political · Spin 32/100 · Headline matches story: yes
“Grandad sues Ozempic maker Novo Nordisk claiming weight loss jab left him partially blind”
Straight reportingHeavy spin
The Daily Mirror centres Jay's experience and legal claim, while reporting the regulatory warnings and urgent UK advice.
Why? 3 framing techniques
emotional appealI feel depression and anger The detailed account of Jay's distress and daily difficulties foregrounds the personal impact of his alleged injury.
emphasisweight loss jab The headline emphasises weight loss, although the article says Jay was prescribed Ozempic for diabetes.
omission The supplied text does not mention that diabetes itself increases the risk of NAION, relevant context for assessing the alleged association.
Manchester Evening NewsFraming: Not political · Spin 25/100 · Headline matches story: yes
“Granddad suing Ozempic maker after claiming weight loss jab 'left him partially-blind'”
Straight reportingHeavy spin
The Manchester Evening News leads with Jay's claim and symptoms, while including Novo Nordisk's denial that causation has been established.
Why? 2 framing techniques
emphasisweight loss jab The headline stresses weight loss, although the story says Jay received the medicine for diabetes.
omission The article does not mention that diabetes itself raises NAION risk or include the MHRA's urgent advice for sudden or rapidly worsening vision loss.
WalesOnlineFraming: Not political · Spin 12/100 · Headline matches story: unknown
“Grandad sues Ozempic makers after claims medication 'left him partially blind'”
Straight reportingHeavy spin
WalesOnline's headline and summary focus on Jay's lawsuit and reported loss of vision; its full article was not supplied.
Why? 1 framing technique
emphasisjust 33% vision in one eye The summary highlights the severity of Jay's reported vision loss without providing wider medical context in the supplied excerpt.
Timeline
2023 — Vandegriff was prescribed Ozempic for diabetes, according to the reports.S1S2
25 December 2024 — Vandegriff says he noticed a smudge in his left eye.S1S2
9 November 2026 — The FDA issued its GLP-1 NAION warning requirement.R1
Earlier coverage of similar events
How outlets reported related stories before this one. Compare for yourself.
This story was written and checked by AI agents using only the sources above, then published automatically. Facts are labelled by how well they are supported. If something is wrong, tell us: we check every report against the sources and publish corrections. Editorial policy
Idaho man sues Ozempic maker over alleged vision loss | NoDirection News